SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

Investors are closely watching IREN's upcoming earnings release and forward guidance, with heavy community debate surrounding short interest and broader AI infrastructure demand.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Traders are closely watching Marvell's upcoming earnings report and forward guidance following a massive revenue forecast from Nvidia, with community discussions heavily focused on AI networking demand and options positioning.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as the community discusses its QNX software expansion into physical AI and robotics alongside broader market reactions.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending as strong cybersecurity sector momentum and ongoing M&A speculation drive heavy call options volume and bullish community sentiment.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trading sharply higher as investors discuss strong earnings results and raised fiscal year guidance, alongside broader optimism in the cybersecurity sector.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is trending as investors debate the massive upcoming release of Grand Theft Auto VI and watch for upcoming trailer reveals and pre-order metrics.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is trading lower as retail investors debate the stock's valuation, recent quarterly earnings, and broader consumer spending trends.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm shares are drawing heavy community discussion as investors closely monitor upcoming earnings, gross merchandise value growth, and key credit delinquency metrics amidst ongoing debate over buy now, pay later sector sentiment.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is rallying strongly past key resistance levels following major news of Charles Schwab expanding its crypto trading platform to include SOL, alongside surging ETF inflows and a corporate treasury accumulation update.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The stock is drawing intense debate as users spar over recent political decisions, trade tensions with Canada, and broader administration policies.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rs 325–4,200/month: Dr Reddy’s, Sun Pharma, Glenmark kick off generic semaglutide price war

… Reddy’s Laboratories, Sun Pharma , Glenmark Pharmaceuticals , Alkem Laboratories, Zydus Lifesciences … , and Natco Pharma . Eris Lifesciences, which has a … first Indian pharma company to receive approval from the Drugs Controller General …

India’s Eris launches $14 monthly generic Ozempic shot, among cheapest globally

India’s Eris Lifesciences on Friday launched one of the most affordable versions of Ozempic so far, with the lowest dosage of generic semaglutide starting at 1,290 rupees ($13.8) per month. Launch under the brand Sundae in India for diabetes, with lowest dose of a Sundae vial, at 2 mg. Natco Pharma, Eris’ partner for the semaglutide launch, priced its lowest 2 mg dose at 1,290 rupees a month. Eris also plans to launch a pen device version of Sundae in April, in three dosages. The lowest 2 mg dose will cost 4,000 rupees per month and the highest 8 mg dose 4,500 rupees per month. Eris is among dozens of Indian drugmakers that are launching generic semaglutide as Danish drugmaker Novo Nordisk’s semaglutide patent is set to expire on March 20. Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India Larger peer Dr Reddy’s is expected to launch on Saturday. Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.

Eris Lifesciences, Natco Pharma ink pact on Semaglutide

Eris Lifesciences has forged a strategic partnership with Natco Pharma for commercialisation of semaglutide in India.

Eris Lifesciences Ltd announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India

… strategic partnership with Natco Pharma Limited for the commercialisation … Natco Pharma has received approval from the Central Drugs Standard … Bulls Keywords ErisLifesciences INE406M01024 Pharmaceuticals Partnership NatcoPharma Semaglutide IndiaLaunch

Natco Pharma, Eris Lifesciences shares jump up to 6% on partnership for Semaglutide launch in India

Shares of Natco Pharma and Eris Lifesciences climbed on Tuesday after announcing a partnership to commercialise Semaglutide in India. Natco rose over 6% to its highest level since January 8, while Eris gained nearly 4%, marking its third straight session of gains.

Eris Lifesciences partners Natco to commercialise semaglutide

Eris Lifesciences has partnered with Natco Pharma to introduce semaglutide in the Indian market a cutting-edge therapy for Type 2 diabetes and obesity management. By combining Eris’s strong commercial network with Natco’s proven production capabilities, the alliance expands Eris’s diabetes care portfolio with a high-impact, next-generation treatment.

Eris Lifesciences/Natco Pharma partner on semaglutide for India

Natco Pharma has received regulatory approval in India, paving the way for a launch in March 2026

Brief India: Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY and more

In this briefing: Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY ICICI Prudential AMC (ICICIAMC IN): Partial Global Index Inclusion with Low Float What Does Silver's Volatility Mean for Markets? Auto Sector Update: India EU FTA Update 1. Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY Overall B2C GOV grew 49% YoY (8.6% QoQ) to reach INR 181.2bn (in-line) Consolidated adj EBITDA losses stood at INR7.1bn (in-line) Food delivery (FD) GOV grew 20.5% YoY to INR 89.6bn (HSIE: INR 88bn) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. 2. Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY We upgrade Eris Lifesciences (Eris) to BUY (from ADD) with a TP of INR 1,730, based on a 28x Q3FY28E EPS (vs 31x Q2FY28E; implies EV/ EBITDA of 16x and PE of 24x for ex-amortization EPS), as we believe since our downgrade to ADD in Jul-25, the stock price has corrected (down 25% in the last six months), which factors in the growth concern in key therapies Now, the valuation has turned attractive (trading at 36/ 26/ 21x on FY25/26/27E PE vs its 5-year average of ~25x) and is providing comfort We expect Eris to focus on the execution phase after its aggressive investments (multiple M&As over FY23–25 and invested INR 38–40bn) for the next few years with focus on anti-diabetic (insulins), obesity (GLP-1) categories, and new FDC launches (~20+ in FY27) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY and more

In this briefing: Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY ICICI Prudential AMC (ICICIAMC IN): Partial Global Index Inclusion with Low Float What Does Silver's Volatility Mean for Markets? Auto Sector Update: India EU FTA Update Union Budget 2026- What We like and What We Don't 1. Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY We upgrade Eris Lifesciences (Eris) to BUY (from ADD) with a TP of INR 1,730, based on a 28x Q3FY28E EPS (vs 31x Q2FY28E; implies EV/ EBITDA of 16x and PE of 24x for ex-amortization EPS), as we believe since our downgrade to ADD in Jul-25, the stock price has corrected (down 25% in the last six months), which factors in the growth concern in key therapies Now, the valuation has turned attractive (trading at 36/ 26/ 21x on FY25/26/27E PE vs its 5-year average of ~25x) and is providing comfort We expect Eris to focus on the execution phase after its aggressive investments (multiple M&As over FY23–25 and invested INR 38–40bn) for the next few years with focus on anti-diabetic (insulins), obesity (GLP-1) categories, and new FDC launches (~20+ in FY27) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Medical Community joins forces on Republic day to address the Silent Crisis of Hypertension at One India Conclave

• Unveils India’s First Hypertension Anthem • National Doctors’ Movement Gains Momentum to Bridge the Diagnosis-to-Control Gap Across India MUMBAI, India, Jan. 27, 2026 /PRNewswire/ — Marking the 77th Republic Day with a call for national health unity, Eris Lifesciences hosted the One India Conclave to address the growing crisis of hypertension in the country. […]

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. Its brands include Eritel, Glimsave, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The firm markets and distributes pharmaceutical drugs, such as tablets, syrups and injections. The company was founded by Amit Indubhushan Bakshi on January 25, 2007 and is headquartered in Ahmedabad, India.

Current Price	1,310.00
Prev Close	1,312.90
Open	1,317.00
Dividend Yield	0.00%
50-Day Moving Average	1,403.74
Beta	0.09
Avg. Volume	95,782.43
PE Ratio	27.91

52-Week High	1,810.80
52-Week Low	1,200.00
Market Capitalization	181.36B
EPS (Annual)	45.33
Price to Book	4.66
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info